Faslodex

Faslodex

fulvestrant

Manufacturer:

AstraZeneca

Marketer:

AstraZeneca
Concise Prescribing Info
Contents
Fulvestrant
Indications/Uses
Postmenopausal women w/ estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy or disease progression on therapy w/ anti-estrogen; estrogen receptor positive, human epidermal growth receptor 2 (HER2) negative locally advanced or metastatic breast cancer not previously treated w/ endocrine therapy.
Dosage/Direction for Use
IM Adult female (including the elderly) 500 mg mthly w/ an additional 500 mg given every 2 wk after initial dose.
Contraindications
Hypersensitivity. Severe hepatic impairment. Pregnancy & lactation.
Special Precautions
Patients w/ bleeding diatheses, thrombocytopenia or taking anticoagulant treatment. Thromboembolic events in women w/ advanced breast cancer. Potential risk of osteoporosis. Administration at dorsogluteal inj site. May result in falsely increased levels of estradiol. May impair ability to drive or operate machinery due to asthenia. Mild to moderate hepatic impairment. Severe renal impairment (CrCl ≥30 mL/min). Women of childbearing potential should be advised to use effective contraception while on treatment. Childn & adolescents.
Adverse Reactions
Hypersensitivity reactions; hot flushes; nausea; elevated hepatic enzymes (ALT, AST, ALP); rash; joint & musculoskeletal pain; asthenia, inj site reactions. UTI; reduced platelet count; anorexia; headache; venous thromboembolism; vomiting, diarrhoea; elevated bilirubin; back pain; vag haemorrhage; peripheral neuropathy, sciatica.
ATC Classification
L02BA03 - fulvestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Faslodex soln for inj 250 mg/5 mL
Packing/Price
(pre-filled syringe) 2 × 1's (Rp15,028,429.00/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in